Uncovered from the forgotten landscape of 'dark genomic matter' , microRNAs (miRNAs) have become rising stars in cancer genetics. miRNAs are small evolutionarily conserved non-coding RNAs of 18-25 nucleotides in length that act as expression regulators of genes involved in fundamental cell processes, such as development, differentiation, proliferation, survival and death 1 . miRNAs are mostly transcribed from intragenic or intergenic regions by RNA polymerase II into primary transcripts of variable length (usually between 1 kb and 3 kb), called pri-miRNAs 2,3 (FIG. 1) . The primary transcripts undergo further processing by the ribonucleases Drosha and DiGeorge syndrome critical region gene 8 (DGCR8) complex in the nucleus, thereby resulting in a hairpin intermediate of about 70-100 nucleotides, called pre-miRNA 4, 5 . The pre-miRNA is then transported out of the nucleus to the cytoplasm by exportin 5 (REF. 6). In the cytoplasm, the pre-miRNA is processed by another ribonuclease, Dicer, into a mature double-stranded miRNA of variable length (~18-25 nucleotides) 7 . After strand separation, the guide strand or mature miRNA is incorporated into an RNA-induced silencing complex (RISC), whereas the passenger strand, denoted with a star (miRNA*) is commonly degraded [8] [9] [10] . The RISC is the effector complex of the miRNA pathway and is comprised of miRNA, argonaute proteins (argonaute 1-argonaute 4) and other protein factors [8] [9] [10] . Argonaute proteins have a crucial role in miRNA biogenesis, maturation and miRNA effector functions [8] [9] [10] . The mature strand is important for target recognition and for the incorporation of specific target mRNAs into the RISC 8-10 (FIG. 1) .
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The specificity of miRNA targeting is defined by Watson-Crick complementarities between positions 2 to 8 from the 5′ miRNA (also known as the seed), with the 3′ untranslated region (UTR) of their target mRNAs 10 . When miRNA and its target mRNA sequence show perfect complementarities, the RISC induces mRNA degradation. Should an imperfect miRNA-mRNA target pairing occur, translation into a protein is blocked 10 . Regardless of which of these two events occur, the net result is a decrease in the amount of the proteins encoded by the mRNA targets.
Each miRNA has the potential to target a large number of genes (on average about 500 for each miRNA family) [11] [12] [13] [14] . Conversely, an estimated 60% of the mRNAs have one or more evolutionarily conserved sequences that are predicted to interact with miRNAs [11] [12] [13] [14] . Bioinformatical analysis predicts that the 3′ UTR of a single gene is frequently targeted by several different miRNAs 11, 12 . Many of these predictions have been validated experimentally, suggesting that miRNAs might cooperate to regulate gene expression 15 .
Besides the aforementioned canonical mechanisms of miRNA gene regulation through 3′ UTR interactions, other 'non-canonical' miRNA-mediated mechanisms of mRNA expression modulation are emerging [16] [17] [18] [19] [20] [21] . Some miRNAs have been shown to bind to the open reading frame or to the 5′ UTR of the target genes and, in some cases, they have been shown to activate rather than to inhibit gene expression 16, 17 . Our group has recently reported that miRNAs can bind to ribonucleoproteins in a seed sequence and a RISC-independent manner and Nature Reviews | Drug Discovery then interfere with their RNA binding functions (decoy activity) 18, 19 . Three studies have reported that miRNAs can also regulate gene expression at the transcriptional level by binding directly to the DNA [20] [21] [22] (FIG. 1) . Overall, these data show the complexity and widespread regulation of gene expression by miRNAs that should be taken into consideration when developing miRNA-based therapies. miRNAs in cancer: a paradigm shift Following our initial demonstration that the mir-15a-mir-16-1 cluster is deleted or downregulated in B cells of patients with chronic lymphocytic leukaemia (Cll) 23 , other studies established that malignant tissues in patients with cancer exhibited distinctive miRNA expression signatures 24, 25 . Genome-wide profiling showed that these miRNA expression signatures allowed different types of cancer to be discriminated with high accuracy 24, 25 and the tissue of origin of poorly differentiated tumours to be identified. By contrast, mRNA profiles were highly inaccurate indicators of tissue or cancer type 24 . Supporting the mechanistic involvement of miRNAs in specific cancers, it was reported that selected groups of distinct miRNAs were commonly and concurrently upregulated or downregulated in distinct types of human neoplasia and were often associated with distinct cytogenetic abnormalities 25 . miR-17 and miR-21 Pol II) into long primary miRNA transcripts of variable size (pri-miRNA), which are recognized and cleaved in the nucleus by the RNase III enzyme Drosha, resulting in a hairpin precursor form called pre-miRNA [1] [2] [3] . b | Pre-miRNA is exported from the nucleus to the cytoplasm by exportin 5 and is further processed by another RNase enzyme called Dicer. c | Dicer produces a transient 19-24 nucleotide duplex [4] [5] [6] [7] . d | Only one strand of the miRNA duplex (mature miRNA) is incorporated into a large protein complex called RNA-induced silencing complex (RISC) [8] [9] [10] . e | The mature miRNA leads RISC to cleave the mRNA or induce translational repression, depending on the degree of complementarity between the miRNA and its target [8] [9] [10] . Although the most frequent site of interaction is the 3′ untranslated region (UTR) of the target mRNA, miRNAs have been described that bind to the open reading frame (ORF) sequences, as well as to the 5′ UTR [16] [17] . This final interaction has been associated with activation rather than repression 17 . f | miRNAs can also bind directly to proteins, in particular RNA-binding proteins, in a sequence dependent manner and prevent these proteins from binding to their RNA targets. These decoy activities of miRNAs are RISC independent 18 . g | miRNAs can also regulate gene transcription by binding directly or by modulating methylation patterns at the target gene promoter level [20] [21] [22] . 32, 39 , lung 28 , colon 33 , breast cancer 31 and in lymphomas [37] [38] Positive regulation by NF-κB 118 Oncogene SHIP1, CEBPB 71, 73 Overexpression AML, acute myeloid leukaemia; BCL-2, B-cell lymphoma protein-2; CCN, cyclin; CDC, cell division cycle; CDKN1A, cyclin-dependent kinase inhibitor 1A; CEBPB, CCAAT/enhancer binding protein β; CLL, chronic lymphocytic leukaemia; CREB, cAMP response element-binding protein; DNMT, DNA methyltransferase; HMGA2, high mobility group AT-hook 2; HSC, haematopoietic stem cells; IL-6, interleukin-6; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue; LATS2, LATS, large tumour suppressor, homologue 2; MCL1, myeloid cell leukaemia sequence 1 (BCL-2-related); NF-κB, nuclear factor-κB; NPM1, nucleophosmin (nucleolar phosphoprotein B23, numatrin); NRAS, neuroblastoma RAS viral (v-ras) oncogene homologue; PDCD4, programmed cell death 4; PTEN, phosphatase and tensin homologue; SHIP1, Src homology 2 domain-containing inositol 5-phosphatase 1; TPM1, tropomyosin 1. were identified to be consistently upregulated in colon, lung, stomach, prostate and pancreatic tumours and miR-155 was discovered to be upregulated in breast, lung and colon cancer 25 . These results have been validated over time in different cohorts of patients and similar results were reported in other types of cancer as well [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (TABLE 1) . By contrast, miR-29 was reported to be downregulated in Cll, acute myeloid leukaemia (AMl), rhabdomyosarcoma, cholangiocarcinoma, mantle cell lymphoma and in lung, breast and liver cancer 28, [30] [31] [32] [40] [41] [42] [43] . In addition miR-15a-miR16-1 was found to be downregulated in Cll, prostate and pituitary adenomas 23, 44, 45 and members of the let-7 family were identified to be downregulated in lung, colon, breast, ovarian and stomach cancer 28, 33, 31, [46] [47] [48] [49] [50] [51] . These commonalities in miRNA expression patterns suggested that deregulation of these miRNAs were unlikely to be a random event in cancer. This led to the hypothesis that upregulated miRNAs may act as oncogenes and downregulated miRNAs may act as tumour suppressors (FIG. 2) . Consequently, similar to the coding genes involved in cancer, it was postulated that genes encoding miRNAs can be subject to genomic alterations leading to expression upregulation, for example, translocations or amplification, or loss of function, for example, deletions, insertions or mutations (FIG. 2) .
Nature Reviews
Consistent with this hypothesis, we discovered that the genes encoding miRNAs are indeed frequently located inside or close to fragile sites and in minimal regions of loss of heterozygosity, in minimal regions of amplification and in common breakpoints associated with cancer 52 . The mir-17-92 cluster, which comprises six miRNAs (mir -17, mir-18a, mir-19a, mir-19b-1, mir-20a and mir-92-1) , is located in an 800 base-pair region of the non-coding gene C13orf25, a genomic region commonly reported to be amplified in lymphomas. The miR-17-92 cluster has frequently been propose that a microRNA (miRNA) that normally downregulates the expression of an oncogene can be defined as a tumour suppressor and is often lost in tumour cells. The loss of function of this miRNA by mutation, deletion, promoter methylation or any abnormalities in the miRNA biogenesis might result in an abnormal expression of the target oncogene, which subsequently contributes to tumour formation by inducing cell proliferation, invasion, angiogenesis and decreased cell death. Some of the proposed mechanisms for the inactivation of miRNAs in cancer are experimentally proved, such as the downregulation of miR-15a-miR-16-1 expression in patients with chronic lymphocytic leukaemia that harbour homozygous and heterozygous deletions at 13q14.3, in which the mir-15a-mir-16-1 cluster is located 23 , and the loss of the mir-29b-1-mir-29a cluster in patients with acute myeloid leukaemia, located in 7q32 (REF. 63 ). In addition, germline mutations were identified in the mir-15a-mir-16-1 precursor, which resulted in lower miR-15a and miR-16-1 expression levels. Overall, the loss of both the mir-15a-mir-16-1 and the mir-29b-1-mir-29a cluster results in the upregulation of target oncoproteins, such as B-cell lymphoma protein-2 (BCL-2), myeloid cell leukaemia sequence 1 (BCL-2-related) (MCL1), TCL1, CDK6 and DNA methyltransferase 3α (DNMT3a) 61, 41, 63, 119, 123 . b | The amplification or overexpression of a miRNA that downregulates a tumour suppressor or other important genes involved in differentiation might contribute to tumour formation by stimulating proliferation, angiogenesis and invasion and by preventing apoptosis and increasing genetic instability. For example, amplifications of the oncogenic miRNAs, mir-17-92 cluster, mir-21 and mir-155, have been clearly associated with tumour initiation and progression by repressing the expression of tumour suppressor genes, such as phosphatase and tensin homologue (PTEN), BIM and programmed cell death 4 (PDCD4) 27, [67] [68] 70 . The effect of the aberrant miRNA expression on the transcriptome and proteome will result in increased cell proliferation, angiogenesis, invasion, anti-apoptosis and genomic instability, which in turn will damage the genome further, perpetuating a dangerous cycle. For example, increased genomic instability may predispose for more mutations that may induce cancer progression or refractoriness to treatment. CEBPB, CCAAT/enhancer binding protein β; PDCD4, programmed cell death 4; RISC, RNA-induced silencing complex; SHIP1, Src homology 2 domain-containing inositol 5-phosphatase 1.
Antisense
The term antisense is generally used for nucleic acid-based approaches that interferes, in a sequence-selective way, with the processing of RNA from its transcription via mRNA to protein or with the effects of other forms of functional RNA.
identified to be overexpressed in solid tumours or in haematological malignancies . By contrast, the mir-15a-mir-16-1 cluster, which is located in the chromosome 13q14 region (between exon 2 and exon 5 of the non-coding gene LEU2), is frequently downregulated in patients with Cll because of genomic deletion of this region 23, 30 (FIG. 2) .
In addition to structural genetic alterations, the silencing of structurally normal miRNA genes by DNA promoter hypermethylation and/or histone hypoacetylation has been described in solid tumours and in haematological malignancies [53] [54] [55] . Saito and colleagues first showed that miR-127 is downregulated owing to promoter hypermethylation in human bladder cancer. It is re-expressed in response to treatment with hypomethylating agents, correlating with a downregulation of the oncogene B-cell lymphoma protein-6 (BCL-6), which is a bona fide target of miR-127 (REF. 53 ).
Aberrant miRNA expression in cancer may also result from downstream miRNA processing (FIG. 2) . Kumar et al. showed that global repression of miRNA expression can be induced by short hairpin RNAs against Dicer and Drosha, the two ribonucleases involved in miRNA processing. They also showed that this treatment promotes cellular transformation and tumorigenesis in vivo 56 . Furthermore, the conditional loss of Dicer1 in the lung tissues of mice enhances the development of lung tumours in a Kras mouse model 56 .
The loss of Dicer and Drosha has also been inversely correlated with outcome in cancers of the ovarian epithelium 57 . Finally, a deregulation of miRNA expression can be a result of increased or decreased transcription from their respective miRNA genes by aberrant transcription factor activity. For example, the miR-34a, miR-34b and miR-34c family of miRNAs was shown to be directly induced by the tumour suppressor p53 and it was suggested that some of the p53 effects could be mediated through the transcriptional activation of miRNAs 58, 59 . Using different models, the authors compared miRNA expression in cells with high or low p53 expression and discovered that miR-34 expression is increased in cells with high p53 levels 58, 59 . Chromatin immunoprecipitation experiments showed that p53 binds to the promoter of miR-34 (REFs 58, 59) .
Recent work also suggests that the oncoprotein MYC negatively regulates transcription of tumour suppressor miRNAs, such as let-7 (let-7a, let-7c, let-7d, let-7f1 and let-7g) and mir-29 family members (mir-29a, mir-29b and mir-29c) 60 . Chromatin immunoprecipitation experiments showed that MYC binds to conserved sequences of the miRNA promoter that it represses. Functionally, it was shown that MYC-induced repression of miRNAs contributes to lymphomagenesis because the restoration of the silenced miRNAs decreases the tumorigenic potential of the lymphoma cells 60 . Nevertheless, despite the advances in our understanding of the mechanisms causing miRNA deregulation, the daunting task is to elucidate the biological role of miRNAs in the initiation and in the development of cancer.
Functional investigations of miRNAs in cancer.
Gainof-function and loss-of-function experiments, in combination with target prediction analyses, have provided insights into the role of miRNAs in carcinogenesis. For example, experiments in which miRNAs that are frequently lost in cancer, such as miR-15a and miR-16 in Cll 23 , were ectopically expressed in leukaemic cells showed that the miR-15a-miR-16-1 cluster overexpression resulted in apoptosis of the leukaemic cells 61 . Target prediction programmes identified BCL-2, a known anti-apoptotic gene, which is upregulated in a subset of patients with Cll, albeit by unknown mechanisms, as the target of miR-15a-miR-16-1 (REF. 61 ). Additional work by our group showed that miR-15a-miR-16-1 directly interact with the BCL-2 3′ UTR and inhibit its protein translation 61 . A negative correlation was also identified between miR-15a-miR-16-1 and BCl-2 protein expression in patients with Cll, supporting this proposed interaction. Thus, the loss of the mir-15a-mir-16-1 cluster in patients with Cll by genomic deletion and mutations results in the unblocking of BCL-2 transcription in Cll cells 61 To assess the biological effects of miRNAs discovered to be overexpressed in cancer cells, in vitro experiments were carried out to block their expression using antisense oligonucleotides. For example, miR-21 expression has been reported at high levels in glioblastomas 34 , pancreas 35 , breast 31 and colon cancer 33 among others (TABLE 1) . Chan and colleagues blocked miR-21 expression in glioblastoma cell lines and reported an increased activation of caspases and of apoptosis 66 . Additional studies showed that miR-21 exerts its anti-apoptotic effects by targeting the tumour suppressors phosphatase and tensin homologue (PTEN) and programmed cell death 4 (REFs 67-68).
The oncogenic activity of the miR-17-92 cluster and of miR-155, both discovered to be overexpressed in lymphoproliferative disorders, including lymphomas and leukaemia 32, 69 , were reported in animal models (FIG. 2;  TABLE 1 ). Infection of murine haematopoietic stem cells with a retrovirus carrying the mir-17-92 cluster accelerated the development of lymphomas in Myc transgenic mice 69 . Transgenic mice that overexpressed the mir-17-92 cluster in B cells were discovered to develop lymphoproliferative disease and autoimmunity 70 . The higher rate of proliferation and the lower rate of activation-induced cell death of lymphocytes in these mice were partially attributed to the direct targeting of the anti-apoptotic genes Bim and Pten by the miR-17-92 cluster 70 . ventura and colleagues showed that mice deficient for mir-17-92 die shortly after birth with lung hypoplasia and a ventricular septal defect 71 . The miR-17-92 cluster is also essential for B cell development as the loss of the mir-17-92 cluster results in the inhibition of B cell development at the pro-B cell to pre-B cell transition 71 . The role of each of the six miRNAs encoded by the mir-17-92 cluster in oncogenesis was investigated by two different groups. Mu and colleagues determined that deletion of the complete mir-17-92 cluster slows Mycinduced oncogenesis 72 . This phenotype was rescued by the reintroduction of the full cluster, but not by the cluster lacking miR-19a and miR-19b, thereby suggesting miR-19 is the most important miRNA of the cluster 72 . Using a different approach, Olive and colleagues overexpressed individual miRNAs in the Eμ-Myc mouse model. The authors discovered that overexpressing the whole cluster, the cluster without mir-92, but not the cluster lacking mir-19a or mir-19b, promotes oncogenesis 73 . Additional studies by both groups identified Pten as the major target for miR-19 (REFs 72, 73) . Altogether, both studies indicate that miR-19 is important for the oncogenic activities of this cluster.
By contrast to the mir-17-92 cluster, overexpression of mir-155 alone in the lymphoid compartment was sufficient to cause cancer and did not require any other cooperative mutation or the expression of Myc. mir-155 transgenic mice developed polyclonal lymphoid proliferation followed by acute lymphocytic lymphoma or leukaemia 74 (FIG. 2; TABLE 1 ). To our knowledge, this was the first report that the dysregulation of a single miRNA can lead to malignancy. Another group reported that the ectopic overexpression of miR-155 in haematopoietic stem cells through infection with retroviral constructs caused a myeloproliferative disorder 75 . Recently, the mechanisms for these effects were discovered. Elegant experiments performed independently by two groups have shown that the Src homology 2 domain-containing inositol 5-phosphatase 1 (SHIP1) is the target of miR-155 (REFs 76, 77) . SHIP1 is expressed in the haematopoietic system and by blocking the AKT pathway it has an important role in the differentiation of macrophages and lymphocytes 78 . Ship1 deficient mice develop a myeloproliferative disorder characterized by increased granulocyte-monocyte populations and decreased B lymphocyte numbers, similar to the phenotype observed for the miR-155 overexpressing mice 76 . Thus, SHIP1 repression by miR-155 seems to be one of the important events for miR-155-induced leukaemogenesis.
In addition to classical tumour suppressor or oncogene functions, miRNAs have recently also been implicated in cell migration and metastasis. It was determined that miR-10a, which is highly expressed in metastatic breast cancer, positively regulates cell migration and invasion 79 . Elegant experiments confirmed that overexpressing miR-10a in non-metastatic breast cancer cells initiates invasion and metastasis 79 . The authors showed that these effects are mediated by the direct targeting of HOXD10 by miR-10a, facilitating the overexpression of the well known pro-metastatic gene RHOC 79 . Furthermore, a recent study reported that silencing mir-10b inhibits metastasis in a mouse breast tumour model, thereby highlighting the therapeutic potential of targeting metastasis-associated miRNAs 80 . Another study showed that miR-126 and miR-335 act as negative regulators of tumour invasion and metastasis in human breast and lung cancer 81 . In FIG. 2, we present a simplified model of miRNAs acting as oncogenes and tumour suppressors. It should be stressed that the function of miRNAs depends on the expression of their crucial targets. Some miRNAs could function as oncogenes in some cell types and as suppressors in others. Thus the definition of miRNAs as oncogenes or as tumour suppressor genes requires an indication of the type of cells in which they act. It is anticipated that this model will need to be refined in the near future as other potentially key aspects of miRNA biology are uncovered. It is unlikely that miRNAs will be responsible for a specific phenotype by aiming at a single target. Instead, it is thought that miRNAs engage in complex interactions with the machinery that controls the transcriptome and concurrently target multiple mRNAs.
Establishing the rationale for targeting miRNAs
The rationale for using miRNAs as anticancer drugs is based on two major findings: that miRNA expression is deregulated in cancer compared with normal tissues and that the cancer phenotype can be changed by targeting miRNA expression [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [47] [48] [49] [50] [51] . The potential advantages of miRNA-based therapeutic approaches over other strategies, such as targeting protein expression, is discussed below.
Unus pro omnibus: 'one for all'. One of the most appealing properties of miRNAs as therapeutic agents is their ability to target multiple genes, frequently in the context of a network, making them extremely efficient in regulating distinct biological cell processes relevant to normal and malignant cell homeostasis 59, 63, 70, [82] [83] [84] (FIG. 3) .
This concept was elegantly shown by the Chen group in their study of T cell receptor biology 84 . It is known that T cell receptor signalling and antigen recognition are controlled by sequential phosphorylation and dephosphorylation events by more than 40 different kinases and phosphatases 84 . miR-181 was shown to have a critical role in the regulation of T cell receptor sensitivity and signalling strength at the post-transcriptional level by targeting multiple phosphatases. More importantly, the authors showed that this task can be carried out efficiently by miR-181a alone, but not by RNA interference a single short hairpin RNA (shRNA), which is designed to target individual genes 84 . The ability of miRNAs to regulate multiple genes in a molecular pathway makes them excellent candidates for novel molecular-targeting treatments.
Cancer networks are connected by miRNA. In cancer, as a result of multiple genetic and epigenetic events, perturbations of important gene and protein networks occur, resulting in malignant transformation. Apoptosis, cell cycle, cell adhesion, chromosome stability and DNA repair networks are frequently affected in carcinogenesis 85 (FIG. 3a) . As miRNAs regulate many different pathways and . Some miRNAs, for example miR-29b, coordinately regulate multiple targets in different pathways 63 . As shown in the figure, miR-29b modulates target mRNAs involved in apoptosis, cell proliferation, DNA methylation, histone acetylation and cell adhesion 63, [118] [119] . b | In this figure we graphically represent a gene-protein network in normal tissues and in cancer. miRNAs are transcribed from miRNA non-coding genes, which have their own transcriptional unit, or from introns of protein-coding genes. In general, one gene is transcribed to one mRNA and translated to one protein. By contrast, miRNAs are transcribed from one or in certain cases from two genes 63, 118 . For example, mir-29b1 is transcribed from chromosome 7 and mir-29b-2 is transcribed from chromosome 1, which are both coding for the same mature sequence. They coordinately regulate multiple mRNAs (shown as a net of connections), thus affecting the output of many proteins. miRNAs have a crucial role in keeping the gene-protein network interconnected. Proteins subsequently regulate gene transcription by directly binding to the gene promoters. In cancer, as a result of mutations, deletion or epigenetic alterations in miRNA genes or in protein-coding genes, aberrant miRNA and mRNA expression occurs, resulting in the expression of oncogenic proteins that cause a certain cancer phenotype. As miRNAs coordinate responses in a network by targeting multiple genes, the perturbation of the miRNA network has a vital function during carcinogenesis causing aberrations in the transcription of large numbers of genes. The miRNA network is 'hijacked' to promote malignancy. By modifying the miRNA network it may be possible to restore homeostasis in cancer. orchestrate integrated responses in normal healthy cells and tissues, it is reasonable to think that they also have key roles in coordinating cancerous networks. One can envision miRNAs as a 'power grid' that keeps all these genes and protein networks connected (FIG. 3b) . The degree of miRNA perturbation in cancer could be measured and compared with normal tissue patterns. This way, it might be possible to obtain a miRNA snapshot map, the 'core of the cancer connectivity grid' . Restoring normal miRNA programmes in the cancer cell may rewire the cell connectivity map and reverse cancer phenotypes. Developing therapeutic strategies to restore homeostasis by modifying miRNA expression may prove to be more comprehensive and successful than targeting individual genes or proteins, as there are only some miRNAs deregulated in cancer, compared with the large perturbations of the transcriptome and proteome in cancer cells. Blocking oncogenic miRNAs using antisense oligo nucleotides. The demonstration that oncogenic miRNAs are upregulated in cancer (TABLE 1) provided a rationale to investigate the use of antisense oligonucleotides to block their expression. Antisense oligonucleotides work as competitive inhibitors of miRNAs, presumably . a | Small-molecule miRNA inhibitors can regulate miRNA expression at the transcriptional level 99 . b | Antisense oligonucleotides can bind to the target miRNAs following the Watson-Crick complementarities and induce either degradation or duplex formation 101, 107 . c | The miR-mask oligonucleotides are synthetic oligonucleotides complementary to the 3′ untranslated region (UTR) target mRNA that compete with endogenous miRNAs for its target 98 . Therefore, the miR-mask is able to block oncogenic miRNA deleterious functions at the target level and activate translation of target mRNAs. d | The miRNA sponges are oligonucleotide constructs with multiple complementary miRNA binding sites (in tandem) to the target miRNA 97 . When introduced to the cell, sponges will 'soak up' endogenous miRNAs, decreasing the expression levels of an oncogenic miRNA. e | Restoring downregulated miRNA expression could be achieved by using synthetic miRNAs (miRNA mimics). f | Restoring downregulated miRNA expression could also be achieved by inserting genes coding for miRNAs into viral constructs, such as the adenovirus-associated vectors (AAV) [100] [101] . EF1α, elongation factor 1 α; GFP, green fluorescent protein; ITR, inverted terminal repeats; ORF, open reading frame; RISC, RNA-induced silencing complex. 
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Phosphorothioate
An oligonucleotide in which the oxygen atom normally linking two consecutive nucleotides has been replaced with sulphur, which resists degradation by cellular enzymes. The phosphorothioate backbone, although reducing affinity to the target RNA, confers considerable stability to nuclease degradation and is essential for in vivo delivery of antisense oligonucleotides to tissues, as the phosphorothioate promotes protein binding and delays plasma clearance.
by annealing to the mature miRNA guide strand and inducing degradation or stoichiometric duplex formation. Although this mechanism was illustrated successfully by injecting complementary double-strand sequences to miRNAs into Drosophila melanogaster embryos 86 , further experiments using naked or unmodified antisense DNA oligonucleotides were ineffective in Caenorhabditis elegans 87 . Researchers overcame these difficulties by introducing modifications to the chemical structure of the oligonucleotides to increase stability, binding affinity and specificity 88 (FIG. 5) . Among these modifications, the introduction of 2′-O-methyl groups contributes to nuclease resistance and improved binding affinities to RNA 87 . Oligonucleotides with 2′-O-methyl groups have proved to be effective inhibitors of miRNA expression in several cancer cell lines [39] [40] [41] 61, 63 . Other modifications, such as the addition of 2′-O-methoxyethyl groups, increases the affinity and the specificity to RNA compared with the 2′-O-methyl analogues 87 . As a proof of principle, Krutzfeldt et al. developed 2′-O-methyl-modified cholesterol-conjugated singlestranded RNA analogues, with phosphorothioate linkages, named 'antagomirs' , complementary to miR-122, which is abundant in the liver. These antagomirs were injected into the tail vein of mice and specific targeting of miR-122 in the liver was observed after 24 hours 89 . The silencing of endogenous miRNAs by this novel method was specific, efficient and long lasting and the effects were still observed 23 days after injection 89 . Gene expression and bioinformatic analysis of the whole transcriptome (mRNA) from antagomir-treated animals showed that the 3′ UTRs of upregulated transcripts were strongly enriched in miR-122 recognition motifs, whereas downregulated genes were depleted of these motifs. Using an antagomir against the ubiquitously expressed miR-16, the authors also investigated the bioavailability and the silencing activity of antagomirs in different tissues. In mice treated with this antagomir, miR-16 was efficiently silenced in all the tissues tested except brain tissue 89 .
Locked nucleic acid (LNA) constructs. lNA nucleosides are a class of nucleic acid analogues in which the ribose ring is 'locked' by a methylene bridge connecting the 2′-O atom and the 4′-C atom (FIG. 5) . By locking the molecule with the methylene bridge, lNA oligonucleotides display unprecedented hybridization affinity towards complementary single-stranded RNA and complementary single-stranded or double-stranded DNA 90 . In addition, they display excellent mismatch discrimination and high aqueous solubility. So-called 'lNA anti-miR' constructs have been used successfully in several in vitro studies to knock down specific miRNA expression 41, 64, 65 . Studies in mice using lNA anti-miR have shown the feasibility and the high efficiency of this approach. Recently, Elmen and colleagues examined whether combining lNA anti-miR with phosphorothioate modifications could improve delivery of the compounds and silence miR-122 in mice without requiring additional chemical modifications 91 . The authors chose to target miR-122 based on previous data that indicated that miR-122 binds to the hepatitis C virus (HCv) and stimulates its replication 92 . In a mouse model, intravenous injections of about 1 mg per kg to 25 mg per kg of such lNA anti-miR showed markedly improved efficiency in antagonizing miR-122 compared with cholesterol-conjugated antagomir that targets miR-122 (REF. 91 ). A previous report indicated that three doses of 80 mg per kg of a cholesterol-conjugated oligonucleotide were needed to silence miR-122 in mice 89 . These data suggest that lNA anti-miRs are able to effectively silence their targets at much lower doses than cholesterol-based oligonucleotides.
The simple systemic delivery of an unconjugated lNA anti-miR-122 (SPC3649, developed by Santaris Pharma) has also been shown to effectively antagonize liver-expressed miR-122 in non-human primates 93 . Using three intravenous doses of 10 mg per kg in African green monkeys, the authors observed an effective depletion of miR-122 in the liver without any evidence of lNA-associated toxicities or histopathological changes in the animals. lNA-mediated antagonism of miR-122 in primates was effective and long lasting 93 . The same group recently investigated the potential of miR-122 antagonism by lNA anti-miR-122 as a new anti-HCv therapy in a chimpanzee model system of chronic infection 94 . The animals were treated at two dose levels (5 mg per kg and 1 mg per kg) by intravenous injections of lNA anti-miR-122, on a weekly basis for 12 weeks, followed by a treatment-free period of 17 weeks. Although a considerable decline in HCv RNA was observed in the serum after 3 weeks of treatment with the higher dose of lNA anti-miR-122, high variability was observed at the lower dose levels 94 . Measurements of miR-122 expression showed substantial and durable silencing in the liver. Furthermore, although there was no evidence of viral resistance or side effects in the treated animals, transcriptome and histological analyses of liver biopsies showed derepression of target mRNAs with miR-122 seed sites, downregulation of interferon-regulated genes and improvement of HCv-induced liver pathology 94 . . B, base.
Overall, these studies not only support the rationale for targeting miR-122 as a new treatment for HCv infection to prevent cirrhosis and associated liver cancer, but also provide proof of principle for antagomir and lNA anti-miR therapies in inflammatory, degenerative or neoplastic human diseases characterized by aberrant upregulation of a specific miRNA family. Indeed, based on these encouraging results, Santaris Pharma is carrying out early clinical studies using SPC3649 in healthy human subjects in Denmark. A clinical Phase I trial, which is currently ongoing, will provide valuable information about pharmacokinetics and safety profiles. miRNA sponges. miRNA sponges are transcripts that contain multiple tandem-binding sites to a miRNA of interest and are transcribed from mammalian expression vectors. Ebert and colleagues recently reported the use of miRNA sponges in mammalian cells 95 . The authors reasoned that miRNA target sequences expressed at high levels could compete with bona fide targets in a cell for miRNA binding. To increase the affinity of these decoy transcripts, the authors introduced not only multiple miRNA binding sites, but also a bulge at the position normally cleaved by argonaute 2, therefore facilitating the stable association of miRNA sponges with ribonucleoprotein complexes loaded with the corresponding miRNA. Using these constructs, a derepression of miRNA targets was observed and indicated effective in vitro silencing of miRNAs 96 . Theses effects were comparable with those obtained with 2′-O-methyl-modified oligonucleotides or lNA antisense oligonucleotides. Furthermore, sponges that contained only the heptameric seed were shown to effectively repress an entire miRNA family that shares by definition the same seed sequence 96 . In a recent study, loya and colleagues applied miRNA sponges to inhibit miRNA activity in transgenic Drosophila in vivo 97 .
The art of disguise: miRmask. miRNA-masking antisense oligonucleotides technology (miR-mask) is another strategy developed by Xiao et al. 98 . In contrast to miRNA sponges, miR-masks consist of single-stranded 2′-O-methyl-modified antisense oligonucleotides that are fully complementary to predicted miRNA binding sites in the 3′ UTR of the target mRNA 98 . In this way, the miR-mask covers up the miRNA-binding site to derepress its target mRNA, thereby its effects are gene specific. This technology has been applied successfully in a zebrafish model to prevent the repressive actions of miR-430 in transforming growth factor-β signalling pathways 98 . Although unwanted effects or off-target effects can be dramatically reduced with this approach, this may be a disadvantage for cancer therapy in which the targeting of multiple pathways might be desirable.
Smallmolecule inhibitors. Several drugs may have the ability to modulate the expression of miRNAs by targeting signalling pathways that ultimately converge on the activation of transcription factors that regulate miRNA encoding genes. Furthermore, it is possible to modulate the machinery that contributes to the miRNA maturation and degradation processes. The identification of these compounds, however, is not straightforward and requires the efficient screening of chemical libraries. Recently, Gumireddy and colleagues identified a method to screen for small-molecule inhibitors of miRNAs 99 . As a proof of principle for this approach, the authors selected miR-21 because this miRNA is frequently upregulated in cancer (TABLE 1) . Complementary sequences to miR-21 were cloned into a luciferase reporter gene, which was then used as a sensor to detect the presence of specific mature miRNA molecules. The construct was transfected into Hela cells, which express high miR-21 levels, resulting in low luciferase activity. Subsequently, a primary screen of more than 1,000 small-molecule compounds was done and an initial hit compound, diazobenzene 1, produced a 250% increase in the intensity of the luciferase signal relative to the untreated cells 99 . Additional characterization showed that this compound affects the transcription of mir-21 (REF. 99 ). This strategy could be applied to the screening of small molecules as inhibitors for other distinct oncogenic miRNAs. These could be used with conventional cancer therapeutics to develop novel combinatorial approaches for cancer treatment.
Restoring tumoursuppressor miRNA expression. The loss or downregulation of a tumour-suppressor miRNA could be overcome by introducing synthetic oligonucleotides that are identical to the selected miRNA, known as miRNA mimics. Introduction of synthetic miRNA mimics with tumour-suppressor function in cancer cells have been shown to induce cell death and block proliferation in several studies [40] [41] [42] 44, 49, 63 . For example, using mimics of miR-15a and miR-29 in prostate and AMl cell lines, respectively, induced apoptosis 44, 63 . These miRNA mimics are small, usually double stranded and chemically modified (2′-O-methyl with phosphorothioate modifications). Some of these include longer sequences such as the miRNA precursor (for example, a pre-miRNA developed by Ambion). It has been reported that intratumoural injections of miR-29 mimics are effective in decreasing tumorigenicity in human rhabdomyosarcoma, liver and AMl xenograft murine models 40, 42, 63 . However, there is no in vivo data using miRNA mimics delivered by intravenous injection.
Another strategy to increase the expression of a tumour-suppressor miRNA in cancer uses adenovirusassociated vectors (AAv). These vectors do not integrate into the genome and are eliminated efficiently with minimal toxicity, as shown in Phase I and Phase II clinical trials of about 200 patients 100, 101 . Another advantage of AAv vectors is the efficient transduction of target cells 100 . The development of self-complementary genome and nonhuman primate AAv serotypes allow more than 90% transduction efficiency of hepatocytes and long-term gene expression without toxicity, following a single systemic administration of recombinant virus 100 . Kota and colleagues recently showed that miR-26 expression was lost in human liver cancers, although it was expressed at high levels in normal tissue 102 . Ectopic expression of this miRNA in liver cancer cell lines was shown to induce cell-cycle arrest. The authors further cloned mir-26 into an AAv vector and viral particles were tested in an established Myc-dependent liver cancer mouse model 102 . Intravenous injection of this miRNA resulted in the suppression of tumorigenicity by inducing tumour apoptosis and by repressing cell growth, without signs of toxicity. Interestingly, considerable anticancer effects were shown even when proteins other than the initiating oncoprotein (MYC) were targeted, for example, cyclin D2 and cyclin E2. This work is the first evidence that restoring the expression of a tumour suppressor miRNA blocks cancer progression in vivo 102 . This strategy could be viable for the treatment of liver cancer, as it is easily targeted by both viral and non-viral gene and small-molecule delivery systems 101 . However, the efficacy of this system for other types of tumours and in different locations is unknown. As there are multiple AAv serotypes available that allow efficient targeting of many tissues of interest, it is possible to target cancers that arise from different tissues. For example, muscle targeting could be desirable for the treatment of soft tissue sarcoma.
Reprogramming cancer cells: turning around a bad network. So far, all the strategies to modulate miRNA expression are designed to modify only one miRNA or a family of miRNAs. As it is likely that miRNAs coordinate in cancer pathogenesis and the phenotypical effects result from multiple interactions between miRNAs and the transcriptome, it is reasonable to search for strategies that aim to reprogramme aberrant miRNA networks in cancer. Reprogramming could be achieved by modulating several of the key miRNAs in a network using antisense oligonucleotides or mimics. However, targeting multiple miRNAs using antisense oligonucleotides or mimics may be technically challenging.
Another strategy to rewire miRNA expression is the use of chemotherapeutic drugs. Several groups reported miRNA expression changes in response to drug treatment in vitro and in vivo 53, 54, 103, 104 , suggesting that such changes may be responsible, at least in part, for the anticancer effects. In acute promyelocytic leukaemia, a subtype of AMl characterized by maturation arrest at the promyelocytic stage and caused by the promyelocytic leukaemia-retinoic acid receptor-α fusion protein, pharmacological doses of all-trans-retinoic acid have been shown to reverse the dominant-negative effect of promyelocytic leukaemia-retinoic acid receptor-α fusion and induce granulocytic differentiation of the AMl blasts and induce apoptosis 103 . Our group reported that the apoptotic effect observed after all-trans-retinoic acid treatment of acute promyelocytic leukaemia cells and of patients is partially explained by all-trans-retinoic acidinduced activation of mir-15a-mir-16-1 cluster expression, which is known to target the expression of the anti-apoptotic protein BCl-2 (REF. 103 ).
Decitabine (Dacogen; Pharmachemie Bv) and 5-azacytidine (Mylosar; Upjohn) are two well-known hypomethylating agents currently approved for the treatment of myelodysplastic syndrome, although they have shown activity in many other malignancies including AMl 105 . It has long been known that these drugs work by DNA methyltransferase inhibition, resulting in tumour suppressor gene re-expression, mediated by promoter hypomethylation 105 . More recently, miRNAs have been shown to be actively re-expressed after treatment with these drugs and have been shown to have important roles for the therapeutic effects of these compounds. It is tempting to suggest that many of the biological effects of decitabine and 5-azacytidine may be mediated by the re-expression of non-coding RNAs [53] [54] [55] . Once a cancer miRNA network is identified, one can envision the use of drugs or other agents to modify the expression of such miRNAs and thereby restore normal patterns of miRNA expression. In a few years, we may be able to generate cell-specific miRNA expression profiles after drug treatment that may facilitate the discovery of functional connections between drugs, genes and diseases, similar to that of the connectivity map -a collection of genome-wide transcriptional expression data from cultured human cells treated with biologically active small molecules 106 . As miRNAs are fewer in number compared with mRNA, it could be assumed that there will be less noise and background in high-throughput-based experiments for miRNAs, such as microarrays, than the ones performed using mRNA 106 . These miRNA-drug maps could then be used to discover novel drug applications and establish drug combination treatments.
Challenges of miRNA-based therapies
The challenges for developing miRNA-based therapeutics are the same as the challenges for small interfering RNA therapeutics and include issues of delivery, potential off-target effects and safety (BOX 1; TABLE 2). One of the major problems for the use of miRNA therapeutics in vivo relates to tissue-specific delivery and to cellular uptake of sufficient amounts of synthetic oligonucleotides to achieve sustained target inhibition 101, 107 . The first obstacle to overcome is the biological instability of these compounds in bodily fluids or tissues, as unmodified 'naked' oligonucleotides are rapidly degraded by cellular and serum nucleases 101, 107 . The second obstacle is the poor cellular uptake of oligonucleotides owing to their size and negative charge, which could prevent them from crossing through cell membranes 101, 107 . To overcome these delivery hurdles, viral and nonviral strategies have been developed
. various chemical modifications in oligonucleotides have been investigated, such as morpholinos, peptide nucleic acids, cholesterol conjugation (see antisense section) and phosphorothioate backbone modifications [108] [109] [110] Although chemical modifications have improved the delivery of oligonucleotides to tissues, this is often associated with impaired biological activity and increased toxicity, in particular when cholesterol-conjugated oligonucleotides are used [108] [109] [110] [111] (TABLE 2) . Other strategies, such as the use of cationic lipids, polymers and nanoparticles, have recently become popular, in an attempt to enhance the cellular uptake and the pharmacological effectiveness of antisense oligonucleotides in vivo 108, [111] [112] [113] . Whereas cationic lipids are too toxic to the cell and elicit hypersensitive reactions in vivo, polymers and nanoparticle strategies are promising because they provide improved delivery and stability with minimal in vivo toxicity 108, [111] [112] [113] 
Finally, because miRNAs regulate many genes, the potential off-target effects of miRNA therapeutics are a major concern, as they may cause toxic phenotypes 101, 108 . As discussed above, in vitro and in vivo data for several types of cancer support the use of miR-29 oligonucleotide mimics as anticancer drugs [40] [41] [42] [43] 63 . Although miR-29 targets several oncogenic pathways, such as apoptosis (MCL1), proliferation (CDK6) and methylation (DNA methyltransferase 1 (DNMT1), DNMT3a and DNMT3b), it also modulates other processes, including bone development 114 , immune function (T helper 1 cell responses) 115 and granulocytic differentiation 63 . Systemic overexpression of miR-29 using a synthetic mimic could target genes, in particular in non-cancerous tissues, and cause unwanted side-effects such as autoimmunity or myeloid hyperproliferation. These problems could be solved by engineering effective systems that deliver the synthetic miRNA oligonucleotides specifically to the diseased tissue and to cancer cells
.
Early clinical trials using DNA antisense technologies showed that severe side-effects, such as cytokine-release syndrome, haematological toxicity (thrombocytopaenia) and liver damage may occur 108, 111 . In some cases, these side effects were mainly owing to problems with formulation, for example liposomes being directly toxic or inducing hypersensitive reactions 111 (TABLE 2) .
In other circumstances they could be related to nonspecific immunological activities triggered by certain CpG motifs in the oligonucleotides that activated mechanisms of innate immunity, mediated by Tolllike cell receptors and other inflamma some effectors, leading to interferon and other cytokine responses 108, 116 (BOX 1). However, no data hitherto suggest that exogenous miRNAs may elicit cytokine responses in mammalian organisms. So far the use of lNA antimiR has proved safe when tested in non-human primates 93, 94 . The ongoing Phase I clinical trial in humans using SPC3649 will be important to assess the safety of this approach (TABLE 2) .
More concerning is a recent report suggesting that toxicity is closely linked to the small RNA concentration. Grim and colleagues elegantly showed that sustained high expression of short hairpin RNAs by AAv vectors induced severe dose-dependent liver damage, owing to interference with endogenous miRNA processing in the liver and resulting in liver-specific miRNA downregulation and injury 117 . As both shRNAs and miRNAs used the same processing pathways 7 , these effects could be explained by the saturation of the processing machinery by exogenous shRNA, leading to loss of miRNA function. This work underscores the challenge for using vector-based therapies to overexpress miRNAs. Similar problems could arise using synthetic mature oligonucleo tides, as they may also saturate RISC and compete and displace other endogenous miRNAs.
miRNA therapeutic applications
What are the potential types of cancer that could be amenable for miRNA-based therapy? Certain miRNAs, such as miR-155, miR-21, miR-17-92 and miR-29, are consistently deregulated in many cancers 25, [27] [28] [29] [30] [31] [32] (TABLE 1) .
Therefore, developing anticancer treatments targeting these miRNAs may be applicable to multiple malignancies. Silencing miR-155 and miR-21 expression in cancer cells would unblock the expression of vital tumour suppressor targets, such as the phosphatases SHIP1 and PTEN, respectively, restoring normal patterns of cell differentiation and proliferation and inducing cancer cell death 73, 67 . As miRNAs, in particular the miR-29 family, have been shown to downregulate DNA methyltransferases (DNMT1, DNMT3a and DNMT3b) and to induce global DNA hypomethylation and tumour-suppressor gene reexpression 118, 119 , restoring miR-29 expression could be used as an epigenetic hypomethylating strategy in malignancies. For example, certain subsets of AMl have been shown to have low miR-29 expression 63 caused by aberrant epigenetic modifications 105 . In addition, owing to their hypomethylating effects, miR-29s are also negative regulators of apoptosis and cell proliferation by targeting the pro-apoptotic MCL1 and the cell cycle regulator
Box 1 | Delivering synthetic microRNAs
To overcome small RNA oligonucelotide delivery hurdles, non-viral and viral strategies have been developed 101, 107 . The non-viral strategies include oligonucleotides with chemical modifications, liposomes, polymers, hydrogels and nanoparticles 101, 107, [109] [110] [111] [112] [113] . The most widely studied oligonucleotide modification is the replacement of each non-bridging oxygen in the backbone with a sulphur atom, thereby forming a phosphorothioate linkage 101, 107 (FIG. 5) . Phosphorothioate oligonucleotides exhibit a dramatically improved in vivo half-life compared with naked oligonucleotides 101, 107 . However, these therapies have generally been administered by continuous intravenous injection and have been associated with several toxicities 101, 107 . The efficacy data from Phase II studies show tumour regression; however, major responses are rare 101, 107 . Liposomes are composed of a phospholipid bilayer with an enclosed aqueous compartment. They interact with oligonucleotides to form complexes stabilized by electrostatic interactions 107, 109 . Cationic liposomes protect oligonucleotides from degradation by nucleases and increase circulating half-time and cellular uptake 107, 109 . However, they are toxic to the cell and elicit hypersensitivity reactions in vivo 109, 110 . Several efforts are underway to make liposomes safer, such as improving their formulation by adding chemical additives to reduce cell toxicity 101, 107 . Another limitation of liposomes is that they tend to accumulate preferentially in the reticuloendothelial system, leading to a short half-life in the serum and reduced access to other tissues 101, 107 . As chemically modified oligonucleotides alone or in combination with liposomes exhibit a short half-life and require either continuous infusion or frequent administration, a possible approach to overcome this problem was to develop sustained-release polymer formulations 112 . Polymers are biodegradable compounds that protect RNA from degradation and facilitate sustained delivery to the tissues 112 .
There are many different types of polymers that vary in size, chemistry and pharmacological properties 101, 112 . In vitro and in vivo studies have shown that biodegradable polymer antisense oligonucleotide combinations achieve sustained delivery and improved tissue biodistribution 112 . More research is still needed to guide the polymer architecture and the chemical structure that are most suited for oligonucleotide delivery and cell and tissue targeting.
Nanoparticles, microspheres and hydrogels have also been developed as gene delivery vehicles. These strategies are promising because they provide improved oligonucleotide delivery and stability with minimal toxicity in animal models 107, 113 . Target-specific delivery could also be achieved by direct injection of the synthetic oligonucleotides into solid tumours. This may be a feasible strategy for mesothelioma (intrapleural injections), ocular tumours, brain tumours or sarcomas and should reduce or eliminate off-target effects. This could also be achieved by tagging nanoparticle-miRNA oligonucleotide complexes with antibodies that bind the desired target cell 101, 107 . For example, one could envisage the development of miR15a-miR-16-1 oligonucleotide nanoparticles coated with CD20-specific antibodies to treat chronic lymphocytic leukaemia. This could be a potential strategy to overcome off-targets effects in haematological cancers.
CDK6, respectively 63 . Thus, therapeutic modulation of miR-29 would affect three pathways deregulated in cancer: epigenetics, apoptosis and cell proliferation or cell cycle (FIG. 3) . miRNAs could also be targeted for therapeutic applications other than cancer. For example, as miR-155 is not only involved in cancer 25, 28 but also in inflammation and immunity 120, 121 , therapies targeting miR-155 could potentially be applicable to various autoimmune and inflammatory disorders.
Future directions
As the miRNA field continues to evolve, a better understanding of miRNA biogenesis and function will certainly affect the development of miRNA-based therapies. miRNA effects are currently largely interpreted as the result of miRNA-mRNA 3′ UTR interactions that cause target post-translational inhibition or degradation. However, focusing on this mechanism to design miRNA therapeutics is likely to prove too simplistic, owing to the emerging miRNA mechanisms, which include decoy activity and 5′ UTR and direct DNA regulatory activities [17] [18] [19] [20] [21] . Research efforts should focus on maximizing the benefit of target diversity, in addition to preventing off-target effects. Improving the chemical design of antisense and miRNA mimics, as well as developing new delivery methods, will be crucial to achieving this goal. Detailed pharmacokinetic and pharmacodynamic studies will be needed to ensure that the desired miRNA concentrations are achieved in tissues and the targets are downregulated. These pharmacokinetic and biological pharmacodynamic effects need to be correlated with the clinical outcome, including treatment responses.
As more miRNA profiling studies are performed after drug treatment in cell lines and in patients, distinctive drug-specific miRNA maps could be obtained. Based on these profiles, it might be possible to use drugs alone or in combination to reprogramme the miRNAome of patients with cancer. We also envisage that miRNA-targeted therapies could be used to enhance or to prevent resistance to standard chemotherapeutic agents or other biological agents. For example, miR-128 has been shown to modulate steroid refractoriness in acute lymphocytic leukaemia, therefore one strategy could be to use a synthetic miRNA in combination with chemotherapy to overcome this problem in the treatment of lymphocytic leukaemia 122 . However, challenges intrinsic to the oligonucleotidebased approaches remain to be overcome, including low bioavailability and poor cellular uptake resulting in suboptimal delivery, as well as off-target effects and long-term safety concerns in humans. New miRNA formulations, including nanoparticles and polymers, as well as virus-based approaches, could be used to overcome these problems. Overall, targeting miRNAs to reprogramme miRNA networks in cancer constitutes a reasonable and evidence-based strategy with a strong potential and chance for success. The enthusiasm for miRNA-based treatments is reflected by the large number of pharmaceutical companies pursuing this strategy. More extensive animal data is needed (in particular with other tumours)
